We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
Read MoreHide Full Article
Thermo Fisher Scientific Inc. (TMO - Free Report) is slated to report first-quarter 2019 results, before the opening bell on Apr 24. In the last reported quarter, the company delivered a positive earnings surprise of 1.88%. Moreover, its key metrics surpassed estimates in the trailing four quarters, recording an average of 3.13%.
Which Way Are Estimates Trending?
The Zacks Consensus Estimate for first-quarter earnings per share is pegged at $2.74, reflecting a year-over-year improvement of 9.6% from the year-ago reported figure.
The same for revenues stands at $6.02 billion, suggesting an improvement of 2.9% over the prior-year reported quarter.
Let’s see how things are shaping up prior to this announcement.
Key Catalysts
With respect to the company’s analytical instruments business, higher global demand, sturdy Thermo Scientific brand, substantial impact from the electron microscopy business, and robust volume expansion and productivity is expected to drive this line of business in the to-be-reported quarter. The Zacks Consensus Estimate for Analytical Instruments revenues is pegged at $1.27 billion, suggesting an improvement of 1.2% from the year-ago reported figure.
Now turning to the life science solutions business, continued strength in the company’s Ion Torrent line of Next-Gen sequences with the GeneStudio S5 series of benchtop instruments and the introduction of Invitrogen EVOS M5000 digital microscope for cell imaging is likely to contribute to the company’s top line in the to-be-reported quarter.
For 2019, the company estimates revenues to range between $24.88 billion and $25.28 billion, resulting in a reported revenue growth of 2-4%.
The company stands to benefit from its successful growth strategy through the launch of innovative products and building scale in high-growth in emerging markets. It is also likely to gain by bolstering customer value proposition.
Other Factors Likely to Influence Q1
The company’s focus on bolstering growth through implementation of strategies and consolidation of product offerings is encouraging. These initiatives might in turn, help it report impressive results during the first quarter.
The company’s aim of expanding capabilities across the rapidly-growing Asia-Pacific belt and the emerging markets is also likely to enhance quarterly results. Outside the United States, the company’s largest market lies in China and it has taken steps to sustain momentum in this market. We expect the company’s commercial infrastructure, in particular, to drive strong growth in the soon-to-be-reported quarter.
Moreover, expected improvement in the applied markets such as environmental and food safeties apart from life science is likely to drive first quarter results.
Turning to Pharma and Biotech, consistent strength in all the businesses serving this end market along with the wide range and depth of capabilities provided to its customer base might boost the company’s performance in the first quarter.
On the back of prudent growth strategy, effective capital deployment, strong analytical instruments business and product portfolio expansion, the company estimates adjusted EPS for 2019 to range between $12 and $12.20 per share, suggesting growth of 8-10% year over year.
Thermo Fisher Scientific Inc. Price and EPS Surprise
However, we are anxious about Thermo Fisher facing a foreign exchange headwind pertaining to 2019 revenues and adjusted EPS. With regards to forex, the company projects year-over-year headwind of about $400 million of revenues or 1.6% and 21 cents per share of adjusted EPS or 1.9% in 2019. The major portion of this headwind is expected in the first half of the year.
Moreover, a hostile macroeconomic condition remains a headwind. Further, stiff competition continues to pose challenges to the stock’s value.
Here’s What the Quantitative Model Predicts:
Our proven Zacks model clearly shows that a company with a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Thermo Fisher has a Zacks Rank #2 and an Earnings ESP of +0.49%, the combination makes us reasonably confident of an earnings beat.
Other Stocks Worth a Look
Here are a few other stocks worth considering from the broader medical space as these too have the right combination of elements to beat on earnings this time around.
Laboratory Corporation of America Holdings (LH - Free Report) has an Earnings ESP of +0.36% and a Zacks Rank #3.
Teleflex Incorporated (TFX - Free Report) has an Earnings ESP of +0.96% and a Zacks Rank #3.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
Thermo Fisher Scientific Inc. (TMO - Free Report) is slated to report first-quarter 2019 results, before the opening bell on Apr 24. In the last reported quarter, the company delivered a positive earnings surprise of 1.88%. Moreover, its key metrics surpassed estimates in the trailing four quarters, recording an average of 3.13%.
Which Way Are Estimates Trending?
The Zacks Consensus Estimate for first-quarter earnings per share is pegged at $2.74, reflecting a year-over-year improvement of 9.6% from the year-ago reported figure.
The same for revenues stands at $6.02 billion, suggesting an improvement of 2.9% over the prior-year reported quarter.
Let’s see how things are shaping up prior to this announcement.
Key Catalysts
With respect to the company’s analytical instruments business, higher global demand, sturdy Thermo Scientific brand, substantial impact from the electron microscopy business, and robust volume expansion and productivity is expected to drive this line of business in the to-be-reported quarter.
The Zacks Consensus Estimate for Analytical Instruments revenues is pegged at $1.27 billion, suggesting an improvement of 1.2% from the year-ago reported figure.
Now turning to the life science solutions business, continued strength in the company’s Ion Torrent line of Next-Gen sequences with the GeneStudio S5 series of benchtop instruments and the introduction of Invitrogen EVOS M5000 digital microscope for cell imaging is likely to contribute to the company’s top line in the to-be-reported quarter.
For 2019, the company estimates revenues to range between $24.88 billion and $25.28 billion, resulting in a reported revenue growth of 2-4%.
The company stands to benefit from its successful growth strategy through the launch of innovative products and building scale in high-growth in emerging markets. It is also likely to gain by bolstering customer value proposition.
Other Factors Likely to Influence Q1
The company’s focus on bolstering growth through implementation of strategies and consolidation of product offerings is encouraging. These initiatives might in turn, help it report impressive results during the first quarter.
The company’s aim of expanding capabilities across the rapidly-growing Asia-Pacific belt and the emerging markets is also likely to enhance quarterly results. Outside the United States, the company’s largest market lies in China and it has taken steps to sustain momentum in this market. We expect the company’s commercial infrastructure, in particular, to drive strong growth in the soon-to-be-reported quarter.
Moreover, expected improvement in the applied markets such as environmental and food safeties apart from life science is likely to drive first quarter results.
Turning to Pharma and Biotech, consistent strength in all the businesses serving this end market along with the wide range and depth of capabilities provided to its customer base might boost the company’s performance in the first quarter.
On the back of prudent growth strategy, effective capital deployment, strong analytical instruments business and product portfolio expansion, the company estimates adjusted EPS for 2019 to range between $12 and $12.20 per share, suggesting growth of 8-10% year over year.
Thermo Fisher Scientific Inc. Price and EPS Surprise
Thermo Fisher Scientific Inc. Price and EPS Surprise | Thermo Fisher Scientific Inc. Quote
However, we are anxious about Thermo Fisher facing a foreign exchange headwind pertaining to 2019 revenues and adjusted EPS. With regards to forex, the company projects year-over-year headwind of about $400 million of revenues or 1.6% and 21 cents per share of adjusted EPS or 1.9% in 2019. The major portion of this headwind is expected in the first half of the year.
Moreover, a hostile macroeconomic condition remains a headwind. Further, stiff competition continues to pose challenges to the stock’s value.
Here’s What the Quantitative Model Predicts:
Our proven Zacks model clearly shows that a company with a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Thermo Fisher has a Zacks Rank #2 and an Earnings ESP of +0.49%, the combination makes us reasonably confident of an earnings beat.
Other Stocks Worth a Look
Here are a few other stocks worth considering from the broader medical space as these too have the right combination of elements to beat on earnings this time around.
Laboratory Corporation of America Holdings (LH - Free Report) has an Earnings ESP of +0.36% and a Zacks Rank #3.
Teleflex Incorporated (TFX - Free Report) has an Earnings ESP of +0.96% and a Zacks Rank #3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.13% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>